We are live on ! Find out more
TGI

TRV GP II Portfolio holdings

AUM $1.34M
1-Year Est. Return 67.55%
This Fund
S&P 500
This Quarter Est. Return
-35.27%
1 Year Est. Return
-67.55%
3 Year Est. Return
-20.84%
5 Year Est. Return
-49.87%
10 Year Est. Return
–
AUM
$176M
AUM Growth
-$357M
Cap. Flow
-$169M
Cap. Flow %
-95.55%
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$125M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$43.2M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JNCE
1
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$78.4M 44.43%
10,230,349
– –
BPMC
2
DELISTED
Blueprint Medicines
BPMC
$55.8M 31.63%
878,875
-1,574,878
-64% -$125M
ALNA
3
DELISTED
Allena Pharmaceuticals
ALNA
$36.4M 20.62%
2,790,964
– –
SAGE
4
DELISTED
Sage Therapeutics
SAGE
$5.85M 3.32%
37,362
– –
MYOK
5
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-885,104
Closed -$43.2M

Similar funds

IVAV
Index Venture Associates V St. Helier, Channel Islands, Jersey $1.46M AUM 88.05% 1-Year Est. Return
VM
Value Monitoring Menlo Park, California $1.5M AUM 13.21% 1-Year Est. Return
CL
CRV LLC Palo Alto, California $1.56M AUM 87.36% 1-Year Est. Return
GAM
GVO Asset Management Zug, Switzerland $1.07M AUM 24.36% 1-Year Est. Return
MC
Manteio Capital Jersey City, New Jersey $1.05M AUM
NC
Noked Capital Tel Aviv, Israel $946K AUM 17.1% 1-Year Est. Return
HCIG
H Capital II GP Grand Cayman, Cayman Islands $1.83M AUM
NP
Nimble Partners San Francisco, California $556K AUM 61.7% 1-Year Est. Return

TRV GP II's Q2 2018 Portfolio in Review

As of Q2 2018, TRV GP II held 5 positions worth $176M, down 67% from $534M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

TRV GP II withdrew a net $169M in Q2 2018, closing 1 position and reducing 1 holding. Its most notable exit was MyoKardia, Inc. Common Stock, an estimated $43.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • TRV GP II's biggest Q2 2018 reduction was Blueprint Medicines, cutting an estimated $125M.
  • TRV GP II fully exited MyoKardia, Inc. Common Stock in Q2 2018, selling an estimated $43.2M.
  • TRV GP II's ten largest holdings make up 100% of its $176M portfolio in Q2 2018.
  • TRV GP II opened 0 new positions and closed 1 in Q2 2018.
  • TRV GP II's portfolio value fell 67% quarter-over-quarter to $176M.

Based on TRV GP II's 13F filing for Q2 2018, filed 7 Aug 2018.